Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review

References

• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
   Web of Science ®Google Scholar
• Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.
   PubMed Web of Science ®Google Scholar
• United States Renal Data System. Chapter 1: CKD in the General Population 2017 [cited 2017 November 15]. Available from: https://www.usrds.org/2017/view/v1_01.aspx
   Google Scholar
• United States Renal Data System. 2017. USRDS Annual Data Report: Executive Summary 2017 [cited 2018 May 29]. Available from: https://www.usrds.org/2017/download/v1_00_ExecSummary_17.pdf
   Google Scholar
• Wang V, Vilme H, Maciejewski ML, et al. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol. 2016;36:319–330.
   PubMed Web of Science ®Google Scholar
• Vekeman F, Yameogo ND, Lefebvre P, et al. Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients. J Med Econ. 2010;13:673–680.
   PubMedGoogle Scholar
• Mujais SK, Story K, Brouillette J, et al. Health-related quality of life in CKD patients: correlates and evolution over time. Clin J Am Soc Nephrol. 2009;4:1293–1301.
   PubMed Web of Science ®Google Scholar
• Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801–2808.
   PubMed Web of Science ®Google Scholar
• Jager KJ, Fraser SDS. The ascending rank of chronic kidney disease in the global burden of disease study. Nephrol Dial Transplant. 2017;32:ii121–ii128.
   PubMedGoogle Scholar
• Braun L, Sood V, Hogue S, et al. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151–163.
   PubMedGoogle Scholar
• World Health Organization. Worldwide prevalence of anaemia 1993–2005 - WHO Global Database on Anaemia. 2008 [cited 2018 October 12]. Available from: http://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsessionid=736CD9E264C858484E244909B38B47DD?sequence=1
   Google Scholar
• Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9:e84943.
   PubMed Web of Science ®Google Scholar
• Rao M, Pereira BJ. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int. 2005;68:1432–1438.
   PubMed Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16:1803–1810.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:192019–192032.
   Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Inter. 2012;2(Suppl.):279–335.
   Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002;17:39–43.
   PubMed Web of Science ®Google Scholar
• Luo J, Jensen DE, Maroni BJ, et al. Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients. Am J Kidney Dis. 2016;68:763–771.
   PubMed Web of Science ®Google Scholar
• Gilbertson DT, Peng Y, Arneson TJ, et al. Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics. BMC Nephrol. 2013;14:44.
   PubMed Web of Science ®Google Scholar
• Roger SD, Tio M, Park HC, et al. Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: a systematic review and meta-analysis. Nephrology (Carlton). 2017;22:969–976.
   PubMed Web of Science ®Google Scholar
• Hougen I, Collister D, Bourrier M, et al. Safety of intravenous iron in dialysis: a systematic review and meta-analysis. CJASN. 2018;13:457–467.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Safety issues in iron treatment in CKD. Semin Nephrol. 2016;36:112–118.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380:447–458.
   PubMed Web of Science ®Google Scholar
• Scornik JC, Bromberg JS, Norman DJ, et al. An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival. BMC Nephrol. 2013;14:217.
   PubMed Web of Science ®Google Scholar
• Tanhehco YC, Berns JS. Red blood cell transfusion risks in patients with end-stage renal disease. Semin Dial. 2012;25:539–544.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes. Chapter 4: Red cell transfusion to treat anemia in CKD. Kidney Int Suppl (2011). 2012;2:311–316.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. 2011 [cited 2018 February 7]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm259639.htm
   Google Scholar
• European Medicines Agency. Abseamed - epoetin alfa. 2019 [cited 2018 February 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000727/WC500020661.pdf
   Google Scholar
• Birnie K, Caskey F, Ben-Shlomo Y, et al. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13. Nephrol Dial Transplant. 2017;32:692–698.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Liu J, Monda KL, et al. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform. J Am Soc Nephrol. 2016;27:3129–3138.
   PubMed Web of Science ®Google Scholar
• Coritsidis GN, Maglinte GA, Acharya A, et al. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013. Clin Ther. 2014;36:408–418.
   PubMed Web of Science ®Google Scholar
• Evans M, Suttorp MM, Bellocco R, et al. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. Nephrol Dial Transplant. 2016;31:628–635.
   PubMed Web of Science ®Google Scholar
• Thamer M, Zhang Y, Kaufman J, et al. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status. Am J Nephrol. 2014;40:554–560.
   PubMed Web of Science ®Google Scholar
• Wang C, Kane R, Levenson M, et al. Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare. JAMA Intern Med. 2016;176:1818–1825.
   PubMed Web of Science ®Google Scholar
• Fuller DS, Bieber BA, Pisoni RL, et al. International comparisons to assess effects of payment and regulatory changes in the United States on anemia practice in patients on hemodialysis: the dialysis outcomes and practice patterns study. J Am Soc Nephrol. 2016;27:2205–2215.
   PubMed Web of Science ®Google Scholar
• Liu H, Yao Y, Cao Y, et al. Anemia management trends in patients on peritoneal dialysis in the past 10 years. Int J Clin Exp Med. 2015;8:18050–18057.
   PubMed Web of Science ®Google Scholar
• McFarlane PA, Pisoni RL, Eichleay MA, et al. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int. 2010;78:215–223.
   PubMed Web of Science ®Google Scholar
• Ryu SR, Park SK, Jung JY, et al. The prevalence and management of anemia in chronic kidney disease patients: result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). J Korean Med Sci. 2017;32:249–256.
   PubMed Web of Science ®Google Scholar
• Zuo L, Wang M, Hou F, et al. Anemia management in the China dialysis outcomes and practice patterns study. Blood Purif. 2016;42:33–43.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Okumura H, Alexandre AF, et al. PUK26 - burden of illness associated with anaemia in chronic kidney disease in japan: a literature review. Value Health. 2017;20:A492.
   Web of Science ®Google Scholar
• van Nooten FE, Green J, Brown R, et al. Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature. J Med Econ. 2010;13:241–256.
   PubMedGoogle Scholar
• Collister D, Komenda P, Hiebert B, et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2016;164:472–478.
   PubMed Web of Science ®Google Scholar
• Furuland H, Linde T, Ahlmen J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353–361.
   PubMed Web of Science ®Google Scholar
• Keown PA, Churchill DN, Poulin-Costello M, et al. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int. 2010;14:168–173.
   PubMed Web of Science ®Google Scholar
• Muirhead N, Keown PA, Churchill DN, et al. Dialysis patients treated with Epoetin alpha show improved exercise tolerance and physical function: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int. 2011;15:87–94.
   PubMed Web of Science ®Google Scholar
• Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol. 2009;4:726–733.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Pisoni RL, Akiba T, et al. Japanese haemodialysis anaemia management practices and outcomes (1999–2006): results from the DOPPS. Nephrol Dial Transplant. 2008;23:3643–3653.
   PubMed Web of Science ®Google Scholar
• Hazara AM, Owen SJ, Bhandari S. The impact of lowering haemoglobin targets on patterns of erythropoiesis-stimulating agent use in patients on haemodialysis. Blood Purif. 2016;41:287–292.
   PubMed Web of Science ®Google Scholar
• Liu J, Guo H, Gilbertson D, et al. Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis. Ther Clin Risk Manag. 2009;5:319–330.
   PubMedGoogle Scholar
• Moyneur E, Bookhart BK, Mody SH, et al. The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. Dis Manag. 2008;11:49–58.
   PubMedGoogle Scholar
• Clement FM, Klarenbach S, Tonelli M, et al. An economic evaluation of erythropoiesis-stimulating agents in CKD. Am J Kidney Dis. 2010;56:1050–1061.
   PubMed Web of Science ®Google Scholar
• Pizzi LT, Patel NM, Maio VM, et al. Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia. Dial Transplant. 2006;35:660–671.
   Google Scholar
• Tonelli M, Winkelmayer WC, Jindal KK, et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003;64:295–304.
   PubMed Web of Science ®Google Scholar
• Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17:97.
   PubMed Web of Science ®Google Scholar
• Okpechi IG, Nthite T, Swanepoel CR. Health-related quality of life in patients on hemodialysis and peritoneal dialysis. Saudi J Kidney Dis Transpl. 2013;24:519–526.
   PubMedGoogle Scholar
• Kubota M, Hiramatsu M, Yamakawa M, et al. Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan. Clin Exp Nephrol. 2011;15:884–892.
   PubMed Web of Science ®Google Scholar
• Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000;11:335–342.
   PubMed Web of Science ®Google Scholar
• Ganz T, Nemeth E. Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol. 2016;36:87–93.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631–1634.
   PubMed Web of Science ®Google Scholar
• Tsukamoto T, Matsubara T, Akashi Y, et al. Annual iron loss associated with hemodialysis. Am J Nephrol. 2016;43:32–38.
   PubMed Web of Science ®Google Scholar
• Wish JB, Aronoff GR, Bacon BR, et al. Positive iron balance in chronic kidney disease: how much is too much and how to tell? Am J Nephrol. 2018;47:72–83.
   PubMed Web of Science ®Google Scholar
• Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4:33–38.
   PubMed Web of Science ®Google Scholar
• Lucca U, Tettamanti M, Mosconi P, et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study. PLoS One. 2008;3:e1920.
   PubMed Web of Science ®Google Scholar
• Thein M, Ershler WB, Artz AS, et al. Diminished quality of life and physical function in community-dwelling elderly with anemia. Medicine (Baltimore). 2009;88:107–114.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Iheanacho I, van Nooten FE, et al., editors. Poster MP198: A systematic literature review of the humanistic burden of anaemia associated with chronic kidney disease. ERA-ERDTA; 2014; Amsterdam.
   Google Scholar
• Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2009;75:15–24.
   PubMed Web of Science ®Google Scholar
• Johansen KL, Finkelstein FO, Revicki DA, et al. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant. 2012;27:2418–2425.
   PubMed Web of Science ®Google Scholar
• Horigan AE. Fatigue in hemodialysis patients: a review of current knowledge. J Pain Symp Manage. 2012;44:715–724.
   PubMed Web of Science ®Google Scholar
• Ju A, Unruh M, Davison S, et al. Establishing a core outcome measure for fatigue in patients on hemodialysis: a Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) consensus workshop report. Am J Kidney Dis. 2018;72:104–112.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Thompson-Leduc P, Rochette S, et al. Economic and humanistic burden of non-dialysis-dependent patients with chronic kidney disease-related anemia: A systematic review. Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting 2018; 2018 Apr 23-26; Boston, MA.
   Google Scholar
• Engelberg AB, Kesselheim AS, Avorn J. Balancing innovation, access, and profits–market exclusivity for biologics. N Engl J Med. 2009;361:1917–1919.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Del Vecchio L, Luise MC. Current and future chemical therapies for treating anaemia in chronic kidney disease. Expert Opin Pharmacother. 2017;18:781–788.
   PubMed Web of Science ®Google Scholar
• Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017;45:127–135.
   PubMed Web of Science ®Google Scholar
• Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016;27:1225–1233.
   PubMed Web of Science ®Google Scholar
• Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32:1373–1386.
   PubMed Web of Science ®Google Scholar
• Haase VH, Chertow GM, Block GA, et al. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2019;34:90–99.
   PubMed Web of Science ®Google Scholar
• Holdstock L, Meadowcroft AM, Maier R, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27:1234–1244.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67:912–924.
   PubMed Web of Science ®Google Scholar
• Bottcher M, Lentini S, Arens ER, et al. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. Br J Clin Pharmacol. 2018;84:1557–1565.
   PubMed Web of Science ®Google Scholar
• Brigandi RA, Johnson B, Oei C, et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial. Am J Kidney Dis. 2016;67:861–871.
   PubMed Web of Science ®Google Scholar
• Hara K, Takahashi N, Wakamatsu A, et al. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015;30:410–418.
   PubMed Web of Science ®Google Scholar
• Meadowcroft AM, Cizman B, Holdstock L, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12:139–148.
   PubMed Web of Science ®Google Scholar
• Angst F, Aeschlimann A, Angst J. The minimal clinically important difference raised the significance of outcome effects above the statistical level, with methodological implications for future studies. J Clin Epidemiol. 2017;82:128–136.
   PubMed Web of Science ®Google Scholar